GleanMark

NEVIA Trademark

NEVIA is a USPTO trademark filed by Enteronova Medical Technologies Inc.. Status: Pending.

Trademark Facts

MarkNEVIA
Serial Number99183535
StatusPending
Filing Date2025-05-13
Mark TypeWord
Nice Classes009 (Electronics & Software), 010 (Medical Devices), 042 (Software & IT), 044 (Medical Services)
OwnerEnteronova Medical Technologies Inc.
Attorney of RecordBrooks Lindsay
Prosecution Events15
Latest EventNOAM on 2026-02-03

Goods & Services

Downloadable mobile application software for providing and optimizing neuromodulation therapy for gut health; Software for managing gastrointestinal and inflammatory conditions through AI-guided transcutaneous cervical vagus nerve stimulation (tcVNS) and transcutaneous auricular vagus nerve stimulation (taVNS); Software for providing and tracking brain-gut axis treatment sessions, providing personalized gut health recommendations, monitoring progress, and interfacing with wearable medical devices.; Providing digital health services in the field of gastroenterology, namely, personalized therapeutic support and remote monitoring for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) through AI-guided neuromodulation therapy; Medical consultation and monitoring services using transcutaneous cervical and auricular vagus nerve stimulation delivered via wearable devices and mobile applications; Health services integrating bioelectronic therapy, symptom tracking, and real-time treatment adjustment to support immune modulation and inflammation reduction.; Non-invasive wearable medical devices for therapeutic neuromodulation, namely, devices that apply simultaneous transcutaneous cervical vagus nerve stimulation (tcVNS) and transcutaneous auricular vagus nerve stimulation (taVNS) for the treatment of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), Crohn’s Disease, and ulcerative colitis; Medical apparatus featuring dual-modality vagus nerve stimulation and AI-powered sensor feedback for modulating immune function and reducing gut inflammation.

Recent Prosecution Activity

DateDocumentType
2026-02-03Notice of AllowanceENA
2025-12-09OG Publication ConfirmationPB3
2025-12-03Notification of Notice of PublicationEB4
2025-12-03Notice of PublicationPB1
2025-11-06Response to Office ActionROA
2025-11-06Amendment and Mail Process CompleteAMC

Related